<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27088" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pharmacodynamics</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Marino</surname>
            <given-names>Mark</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jamal</surname>
            <given-names>Zohaib</given-names>
          </name>
          <aff>Rawalpindi Medical University, Rawalpindi</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zito</surname>
            <given-names>Patrick M.</given-names>
          </name>
          <aff>University of Miami; Miller School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mark Marino declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Zohaib Jamal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Zito declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27088.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>f"Did we but know the mechanical affections of the particles of rhubarb, hemlock, opium, and a man...we should be able to tell beforehand that rhubarb will purge, hemlock kill, and opium make a man sleepy..." -&#x000a0;John Locke:&#x000a0;<italic toggle="yes">Essay Concerning Human Understanding </italic></p>
        <p>Pharmacodynamics studies a drug's molecular, biochemical, and physiologic effects or actions. It comes from the Greek words&#x000a0;"pharmakon,"&#x000a0;meaning "drug," and "dynamikos," meaning "power."&#x000a0;All drugs produce their effects by interacting with biological structures or targets at the molecular level to induce a change in how the target molecule functions regarding subsequent intermolecular interactions. These interactions include receptor binding, post-receptor effects, and chemical interactions. Examples of these interactions include drugs binding to an active site of an enzyme, drugs that interact with cell surface signaling proteins to disrupt downstream signaling, and drugs that act by binding molecules like tumor necrosis factor.<xref ref-type="bibr" rid="article-27088.r1">[1]</xref>&#x000a0;</p>
        <p>After the drug-target interaction occurs downstream, effects are elicited, which can be measured by biochemical or clinical means. Examples include the inhibition of platelet aggregation after administering aspirin, reduction of blood pressure after ACE inhibitors, and the blood-glucose-lowering effect of insulin.<xref ref-type="bibr" rid="article-27088.r2">[2]</xref><xref ref-type="bibr" rid="article-27088.r3">[3]</xref>&#x000a0;While these examples seem obvious, the administration of the preceding drug examples should be kept in mind, so practitioners do&#x000a0;not administer these drugs to inhibit platelet aggregation, lower blood pressure, or lower blood glucose but to reduce the risks of cerebrovascular accident, myocardial infarction,&#x000a0;and renal and eye complications through the drug's pharmacodynamic effects.<xref ref-type="bibr" rid="article-27088.r4">[4]</xref>&#x000a0;Healthcare practitioners must treat the patient, not the symptom or the lab value. Pharmacodynamics and pharmacokinetics are the&#x000a0;2 branches of pharmacology, with pharmacodynamics studying the action of the drug on the organism and pharmacokinetics studying the effect the organism has on the drug.</p>
        <p>Pharmacodynamic actions include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Stimulating activity by directly inhibiting a receptor and its downstream effects</p>
          </list-item>
          <list-item>
            <p>Depressing activity by direct receptor inhibition and its downstream effects</p>
          </list-item>
          <list-item>
            <p>Antagonistic or blocking a receptor by binding to&#x000a0;it but not activating it</p>
          </list-item>
          <list-item>
            <p>Stabilizing action, where the drug behaves as neither an agonist nor antagonist&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Direct chemical reactions (beneficial in therapy and also as an adverse event)</p>
          </list-item>
        </list>
        <p>Any&#x000a0;of these factors can work therapeutically and precipitate an adverse event.</p>
      </sec>
      <sec id="article-27088.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>
<bold>Pharmacodynamic Concepts</bold>
</p>
        <p>Pharmacodynamics describes the extent and duration of a drug's action using a few key concepts and terms:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Emax</bold> is the maximal effect of a drug on a parameter&#x000a0;being measured. For example, this could be a measure of platelet inhibition as an <italic toggle="yes">ex-vivo</italic> test or the maximum lowering of blood pressure.</p>
          </list-item>
          <list-item>
            <p><bold>EC50</bold>&#x000a0;is the drug concentration at a steady state that produces half of the maximum effect.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Hill coefficient&#x000a0;</bold>is the slope of the relationship between drug concentration and drug effect. Hill coefficient values above 2 indicate a steep relationship (ie, small changes in concentration produce significant changes in effect), and hill coefficient values above 3 indicate an almost instantaneous "all or none" effect.<xref ref-type="bibr" rid="article-27088.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>General Mechanisms of Drug Actions</bold>
</p>
        <p>Drugs produce their effects by interacting with biological targets, but the time course of the pharmacodynamic effect is dependent on the mechanism and biochemical pathway of the target. Effects can be classified as direct or indirect and immediate or delayed. Direct effects are usually the result of drugs interacting with a receptor or enzyme central to the effect's pathway. Beta-blockers inhibit receptors that directly modulate cAMP levels in smooth muscle cells in the vasculature. Indirect effects result from drugs interacting with receptors and proteins of other biologic structures significantly upstream from the end biochemical process that produces the drug effect. Corticosteroids bind to nuclear transcription factors in the cell cytosol, which translocate to the nucleus and inhibit DNA transcription to mRNA encoding for several inflammatory proteins.<xref ref-type="bibr" rid="article-27088.r6">[6]</xref></p>
        <p>Immediate effects are usually secondary to direct drug effects. Neuromuscular blocking agents such as succinylcholine, which consists of&#x000a0;2 acetylcholine molecules linked end to end by their acetyl groups, interact with the nicotinic acetylcholine receptor on skeletal muscle cells and leave the channel in an open state, resulting in membrane depolarization and generation of an action potential, muscle contraction and then paralysis within 60 seconds after administration.<xref ref-type="bibr" rid="article-27088.r7">[7]</xref> Delayed effects can be secondary to direct drug effects. Chemotherapy agents that interfere with DNA synthesis, like cytosine arabinoside, which is used in acute myeloid leukemia, produce bone marrow suppression that occurs several days after administration.</p>
        <p>
<bold>Dosing Principles-Based Upon Pharmacodynamics</bold>
</p>
        <p>Pharmacodynamics&#x000a0;emphasizes dose-receptor relationships, the interactions between the drug's concentration and its effect.<xref ref-type="bibr" rid="article-27088.r8">[8]</xref>&#x000a0;For example, we can examine drug-receptor interactions according to the following formula:</p>
        <p>In this equation, L&#x000a0;represents the ligand, ie,&#x000a0;drug concentration, R denotes receptor concentrations, and LR is the ligand-receptor complex concentrations.</p>
        <p>Other pharmacodynamic concepts include:</p>
        <p>Kd: The pharmacologic response depends on the drug binding to its target as well as&#x000a0;the concentration of the drug at the receptor site.&#x000a0;Kd measures how tightly a drug binds to its receptor. Kd is the ratio of rate constants for association (kon) and dissociation (koff) of the drug to and from the receptors. At equilibrium, the rate of receptor-drug complex formation is equal to the rate of dissociation into its components receptor + drug. The measurement of the reaction rate constants can be used to define an equilibrium or affinity constant (1/Kd). The smaller the Kd&#x000a0;value, the greater the affinity of the antibody for its target. For example, albuterol has a Kd of 100 nanomolar&#x000a0;(nM) for the beta-2 receptor.&#x000a0;</p>
        <p>Receptor Occupancy: According to the law of mass action, the more receptors the drug occupies, the greater the pharmacodynamic response. However, all receptors need not be occupied to get a maximal response. This principle is the concept of spare receptors, which commonly includes muscarinic and nicotinic acetylcholine, steroid, and catecholamine receptors. Maximal effects are obtained by less than maximal receptor occupancy by signal amplification.</p>
        <p>Receptor Up- and Downregulation: Chronic exposure of a receptor to an antagonist typically leads to upregulation or an increased number of receptors, while chronic exposure of a receptor to an agonist causes downregulation or decreased receptors.<xref ref-type="bibr" rid="article-27088.r9">[9]</xref>&#x000a0;Other mechanisms involving alteration of downstream receptor signaling may also be involved in up- or downmodulation without altering the receptor number on the cell membrane.<xref ref-type="bibr" rid="article-27088.r10">[10]</xref>&#x000a0;The insulin receptor undergoes downregulation due to chronic exposure to insulin. The number of surface receptors for insulin is gradually reduced by receptor internalization and degradation brought about by increased hormonal binding. An exception to the rule is the receptor for nicotine that demonstrates upregulation in receptor numbers upon extended exposure to nicotine despite nicotine being an agonist, which explains some of its addictive properties.</p>
        <p>Effect compartment and indirect pharmacodynamics: A delay between the appearance of the drug in the plasma and its intended effect may be due to multiple factors, including transfer into the tissue or cell compartment in the body or a requirement for the inhibition or stimulation of a signal to be cascaded through intracellular pathways. These effects can be described using an effect compartment or indirect pharmacodynamic response models, which describe the drug's effect through indirect mechanisms such as inhibition or stimulation of the production or elimination of endogenous cellular components that control the effect pathway.<xref ref-type="bibr" rid="article-27088.r11">[11]</xref></p>
      </sec>
      <sec id="article-27088.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Several issues in drug dosing can be explained in terms of Kd, receptor occupancy, and up/downregulation. Tolerance to a drug, where the effects seem to diminish with continued dosing, frequently occurs with prolonged dosing of opioids. Activation of opioid receptors stimulates the production of intracellular proteins called arrestins. Arrestins bind to the intracellular portion of the opioid receptor, block G-protein signaling, and induce receptor endocytosis. This results in less "signaling" or tolerance. The activity of arrestins, which produce receptor down-regulation, is&#x000a0;1 of the many pathways that lead to opioid tolerance.<xref ref-type="bibr" rid="article-27088.r10">[10]</xref></p>
      </sec>
      <sec id="article-27088.s4" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The goal of pharmacodynamics in a pharmacological therapy setting is to exert positive effects at the least necessary dose that produces the maximum therapeutic effect while minimizing the pharmacodynamics that lead to an adverse event. All interprofessional healthcare team members engaged in prescribing, dosing, dispensing, or administering pharmacological therapy must understand pharmacodynamic and pharmacokinetic principles. The level of knowledge&#x000a0;must be commensurate with the practitioner's clinical function. However, pharmacologic therapy properly involves an interprofessional team that includes all clinicians who prescribe or order medications (MDs, DOs, NPs, PAs), pharmacists, who without question need to be the subject matter experts regarding pharmacodynamics and their application in drug therapy;&#x000a0;clinicians should utilize them as a valuable resource because of this specialization, and nurses, who along with the pharmacists can counsel the patient about their medications, administer them in inpatient and other settings, and are often the main point of contact for patients regarding their drug regimen. An interprofessional team approach to pharmacotherapy that includes appropriate pharmacodynamic knowledge can optimize patient outcomes while minimizing adverse events.</p>
      </sec>
      <sec id="article-27088.s5">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27088&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27088">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27088/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27088">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27088.s6">
        <title>References</title>
        <ref id="article-27088.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rang</surname>
                <given-names>HP</given-names>
              </name>
            </person-group>
            <article-title>The receptor concept: pharmacology's big idea.</article-title>
            <source>Br J Pharmacol</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>147 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>S9</fpage>
            <page-range>S9-16</page-range>
            <pub-id pub-id-type="pmid">16402126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27088.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cirillo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Taglialatela</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pellegrino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Morello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Conte</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Serafino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cimmino</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>468</fpage>
            <page-range>468-472</page-range>
            <pub-id pub-id-type="pmid">32335777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27088.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Di</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.</article-title>
            <source>Emerg Microbes Infect</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>757</fpage>
            <page-range>757-760</page-range>
            <pub-id pub-id-type="pmid">32228222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27088.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keller</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hann</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacodynamics: Principles of Drug Response and Alterations in Kidney Disease.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2018</year>
            <month>Sep</month>
            <day>07</day>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>1413</fpage>
            <page-range>1413-1420</page-range>
            <pub-id pub-id-type="pmid">29769182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27088.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goutelle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maurin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rougier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barbaut</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Bourguignon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ducher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maire</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The Hill equation: a review of its capabilities in pharmacological modelling.</article-title>
            <source>Fundam Clin Pharmacol</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>633</fpage>
            <page-range>633-48</page-range>
            <pub-id pub-id-type="pmid">19049668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27088.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramamoorthy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cidlowski</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Corticosteroids: Mechanisms of Action in Health and Disease.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-31, vii</page-range>
            <pub-id pub-id-type="pmid">26611548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27088.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jonsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dabrowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gurley</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Larsson</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Fredholm</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>LI</given-names>
              </name>
            </person-group>
            <article-title>Activation and inhibition of human muscular and neuronal nicotinic acetylcholine receptors by succinylcholine.</article-title>
            <source>Anesthesiology</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>104</volume>
            <issue>4</issue>
            <fpage>724</fpage>
            <page-range>724-33</page-range>
            <pub-id pub-id-type="pmid">16571968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27088.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lees</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Principles of pharmacodynamics and their applications in veterinary pharmacology.</article-title>
            <source>J Vet Pharmacol Ther</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>397</fpage>
            <page-range>397-414</page-range>
            <pub-id pub-id-type="pmid">15601436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27088.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dumas</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.</article-title>
            <source>AAPS J</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>537</fpage>
            <page-range>537-51</page-range>
            <pub-id pub-id-type="pmid">18989788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27088.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cahill</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Walwyn</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>AMW</given-names>
              </name>
              <name>
                <surname>Pradhan</surname>
                <given-names>AAA</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Allostatic Mechanisms of Opioid Tolerance Beyond Desensitization and Downregulation.</article-title>
            <source>Trends Pharmacol Sci</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>11</issue>
            <fpage>963</fpage>
            <page-range>963-976</page-range>
            <pub-id pub-id-type="pmid">27670390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27088.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jusko</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Characteristics of indirect pharmacodynamic models and applications to clinical drug responses.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1998</year>
            <month>Mar</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>229</fpage>
            <page-range>229-39</page-range>
            <pub-id pub-id-type="pmid">9517366</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
